Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Tissue Engineering. Part C, Methods
|
December 6, 2019
An <i>Ex Vivo</i> Bone Defect Model to Evaluate Bone Substitutes and Associated Bone Regeneration Processes
Tim Klüter, Rywan Hassan, Alexander Rasch, et al.
Journal of Medicinal Chemistry
|
August 8, 2024
Novel Small-Molecule Atypical Chemokine Receptor 3 Agonists: Design, Synthesis, and Pharmacological Evaluation for Antiplatelet Therapy
Alp Bayrak, Martyna Szpakowska, Valerie Dicenta-Baunach, et al.
Journal of Medicinal Chemistry
|
May 22, 2025
A "Ligand First" Approach toward Selective, Covalent JNK2/3 Inhibitors
Valentin R Wydra, Nicole Plank, Stefan Zwirner, et al.
Journal of Medicinal Chemistry
|
April 11, 2024
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S<sub>N</sub>Ar Electrophiles
Moritz Schwarz, Maksym Kurkunov, Florian Wittlinger, et al.
RSC Medicinal Chemistry
|
August 4, 2025
A twist in the tale: shifting from covalent targeting of a tyrosine in JAK3 to a lysine in MK2
Laura Hillebrand, Guiqun Wang, Alexander Rasch, et al.
Journal of Medicinal Chemistry
|
December 16, 2024
Design, Synthesis, and Biochemical Evaluation of Novel MLK3 Inhibitors: A Target Hopping Example
Pascal Sander, Martin P Schwalm, Andreas Krämer, et al.
Research Square
|
October 4, 2023
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors
David Heppner, Florian Wittlinger, Blessing Ogboo, et al.
Journal of Medicinal Chemistry
|
July 13, 2026
Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors
Xiaojun Julia Liang, Claudia Albertini, Thales Kronenberger, et al.
ACS Pharmacology & Translational Science
|
April 18, 2024
Correction to "Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity"
Philipp Flury, Julian Breidenbach, Nadine Krüger, et al.
ACS Pharmacology & Translational Science
|
February 15, 2024
Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity
Philipp Flury, Julian Breidenbach, Nadine Krüger, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Tissue Engineering. Part C, Methods
|
December 6, 2019
An <i>Ex Vivo</i> Bone Defect Model to Evaluate Bone Substitutes and Associated Bone Regeneration Processes
Tim Klüter, Rywan Hassan, Alexander Rasch, et al.
Journal of Medicinal Chemistry
|
August 8, 2024
Novel Small-Molecule Atypical Chemokine Receptor 3 Agonists: Design, Synthesis, and Pharmacological Evaluation for Antiplatelet Therapy
Alp Bayrak, Martyna Szpakowska, Valerie Dicenta-Baunach, et al.
Journal of Medicinal Chemistry
|
May 22, 2025
A "Ligand First" Approach toward Selective, Covalent JNK2/3 Inhibitors
Valentin R Wydra, Nicole Plank, Stefan Zwirner, et al.
Journal of Medicinal Chemistry
|
April 11, 2024
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S<sub>N</sub>Ar Electrophiles
Moritz Schwarz, Maksym Kurkunov, Florian Wittlinger, et al.
RSC Medicinal Chemistry
|
August 4, 2025
A twist in the tale: shifting from covalent targeting of a tyrosine in JAK3 to a lysine in MK2
Laura Hillebrand, Guiqun Wang, Alexander Rasch, et al.
Journal of Medicinal Chemistry
|
December 16, 2024
Design, Synthesis, and Biochemical Evaluation of Novel MLK3 Inhibitors: A Target Hopping Example
Pascal Sander, Martin P Schwalm, Andreas Krämer, et al.
Research Square
|
October 4, 2023
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors
David Heppner, Florian Wittlinger, Blessing Ogboo, et al.
Journal of Medicinal Chemistry
|
July 13, 2026
Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors
Xiaojun Julia Liang, Claudia Albertini, Thales Kronenberger, et al.
ACS Pharmacology & Translational Science
|
April 18, 2024
Correction to "Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity"
Philipp Flury, Julian Breidenbach, Nadine Krüger, et al.
ACS Pharmacology & Translational Science
|
February 15, 2024
Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity
Philipp Flury, Julian Breidenbach, Nadine Krüger, et al.
Page
of 3